Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atx08-001. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 16/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atx08-001 SCHEMBL29691565 | 1.00 | PPARG (1.00) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| Atx08-001 SCHEMBL29368164 | 1.00 | PPARG (1.00) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1160177 | 0.97 | PPARG (0.95) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7650777 | 0.95 | PPARG (0.91) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6301169 | 0.91 | PPARG (0.84) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7650977 | 0.91 | PPARG (0.84) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6303490 | 0.91 | PPARG (0.84) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6301327 | 0.91 | PPARG (0.83) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6308137 | 0.91 | PPARG (0.83) | PPARGHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1160303 | 0.90 | PPARG (0.82) | PPARGHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3199203-B1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2020-02-05 | — | — | EP | claimed |
| US-20140024692-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | AESTUS THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | claimed |
| US-8563589-B2 | Methods of treating neuropathic pain with benzimidazole derivative agonists of PPARgamma | SAMEEVE CORP | 2013-10-22 | — | — | US | claimed |
| EP-2459192-A1 | METHODS OF TREATING NEUROPATHIC PAIN WITH BENZIMIDAZOLE DERIVATIVE AGONISTS OF PPARGAMMA | Aestus Therapeutics, Inc. (US) | 2012-06-06 | — | — | EP | claimed |
| WO-2011014600-A1 | METHODS OF TREATING NEUROPATHIC PAIN WITH BENZIMIDAZOLE DERIVATIVE AGONISTS OF PPARGAMMA | AESTUS THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20110028527-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | AESTUS THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | claimed |
| EP-1731170-A1 | THERAPEUTIC AGENT FOR DIABETES CONTAINING INSULIN RESISTANCE IMPROVING AGENT | Sankyo Company, Limited (JP) | 2006-12-13 | — | — | EP | claimed |
| WO-2005082414-A2 | CONCOMITANT DRUGS OF A SULFONAMIDE AND ANOTHER THERAPEUTIC AGENT | ASTELLAS PHARMA INC. (JP) | 2005-09-09 | — | — | WO | claimed |
| US-20050197376-A1 | Concomitant drugs | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-09-08 | — | — | US | claimed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | claimed |
| US-6703410-B1 | HYPOGLYCEMIC AGENTS; CRYSTALLOGRAPHICALLY PURE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-09 | — | — | US | claimed |
| EP-1138674-A1 | CRYSTALLINE FORMS OF 3-(2,4-DICHLOROBENZYL)-2-METHYL-N-(PENTYLSULFONYL)-3H-BENZIMIDAZOLE-5-CARBOXAMIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-04 | — | — | EP | claimed |
| EP-1132087-A1 | REMEDIES FOR POLYCYSTIC OVARY SYNDROME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-12 | — | — | EP | claimed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | claimed |
| US-20240423967-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2024-12-26 | — | — | US | disclosed |
| US-12083107-B2 | Pharmaceutical compositions comprising glitazones and Nrf2 activators | Kahrs, Bjoern Colin (CH) | 2024-09-10 | — | — | US | disclosed |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | KAHRS, Bjoern Colin (CH) | 2023-06-22 | — | — | US | disclosed |
| WO-2000029383-A1 | CRYSTALLINE FORMS OF 3-(2,4-DICHLOROBENZYL)-2-METHYL-N-(PENTYLSULFONYL)-3H-BENZIMIDAZOLE-5-CARBOXAMIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000029383-A1 | CRYSTALLINE FORMS OF 3-(2,4-DICHLOROBENZYL)-2-METHYL-N-(PENTYLSULFONYL)-3H-BENZIMIDAZOLE-5-CARBOXAMIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-25 | — | — | WO | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423967-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | PPARG 1/4885HDAC3 268/4885HDAC4 283/4885 |
| US-20140024692-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | PPARG, PPARA, PPARD | PPARG 1/4885HDAC3 35/4885HDAC4 180/4885 |
| US-20110028527-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | PPARG, PPARA, PPARD | PPARG 1/4885HDAC3 35/4885HDAC4 180/4885 |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | PPARG 1/4885HDAC3 268/4885HDAC4 283/4885 |
| US-12083107-B2 | Pharmaceutical compositions comprising glitazones and Nrf2 activators | PPARG, PPARA, PPARD | PPARG 1/4885HDAC3 268/4885HDAC4 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.